Acute Kidney Injury Clinical Trial
— PREVENTS-AKIOfficial title:
PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care
Background Acute Kidney Injury (AKI) is a potentially life-threatening condition caused by unsafe levels of fluid and waste products accumulating in the body. Often, patients with AKI need treatment with an artificial kidney (called renal replacement therapy or dialysis) to do the work of their kidneys and remove these dangerous levels of fluid and waste from the body. If left untreated, AKI can become a chronic (long-term) condition that may require treatment for life. Dapagliflozin is a medication used to treat patients with diabetes, heart disease and long-term (chronic) kidney disease. Recently, Dapagliflozin has been shown to slow the progression of other kidney related complications, however this has not yet been studied in critically ill patients. Aim To determine if giving Dapagliflozin (one tablet a day) compared to placebo (a tablet that looks identical but has no active ingredients), decreases injury to the kidneys in patients admitted to the Intensive Care Unit. Design This study will enrol 3000 patients from 45-50 hospitals worldwide. It is a 'randomised controlled trial' meaning patients will be randomly assigned (like tossing a coin) by a computer to receive either Dapagliflozin or placebo for a maximum of 30 days whilst in the ICU. The study is also a 'double blinded trial' meaning that neither the doctor, the intensive care staff or the patient will know which study treatment they are receiving.
Status | Recruiting |
Enrollment | 3000 |
Est. completion date | March 1, 2027 |
Est. primary completion date | August 31, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age 18 years or more - Admitted to ICU within the last 7 days - Expected to be in the ICU the day after tomorrow - An arterial or central venous catheter is in situ, or placement is planned for routine management - Able to receive study treatment orally or via enteral route - At least one of the following risk factors for AKI: - Required fluid resuscitation, defined as a bolus of fluid prescribed to be given over =1 hour to increase or maintain intravascular volume that is in addition to maintenance fluids - Being treated with continuous vasopressors or inotropes to maintain a systolic blood pressure > 90mmHg, or mean arterial blood pressure > 60mmHg or a MAP target set by the treating clinician for maintaining perfusion - At least one of the following pre-morbid risk factors: - Treatment for high blood pressure - Treatment for type 2 diabetes (minimum diet therapy) - Atherosclerotic cardiovascular disease - History of heart failure - Impaired renal function, defined as an eGFR between 20 - 60 mL/min/1.73m2 - Estimated BMI 30 kg/m2 or more - Age 60 years or more Exclusion Criteria: - Met all inclusion criteria more than 24 hours ago - History of type 1 diabetes mellitus or diabetic ketoacidosis - COVID-19 infection as the reason for ICU admission - Requiring renal replacement therapy for intoxication - eGFR less than 20 mL/min/1.73m2 - Known hypersensitivity to any SGLT-2 inhibitor e.g. dapagliflozin, canagliflozin, empagliflozin, ertugliflozin - Solid organ transplantation within the last 12 months - Likely to be transferred to another hospital in the next 3 days - Known or suspected pregnancy - Death is deemed imminent or inevitable - Life expectancy is estimated to be less than 90 days - Patient or the treating clinician declines to participate - Enrolled in another interventional trial for which co-enrolment is not approved - Patient has previously been enrolled in the PREVENTS-AKI Study |
Country | Name | City | State |
---|---|---|---|
Australia | Grampians Health | Ballarat | Victoria |
Australia | Austin Health | Heidelberg | Victoria |
Lead Sponsor | Collaborator |
---|---|
The George Institute | Australian and New Zealand Intensive Care Society Clinical Trials Group, University Medical Center Groningen |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Composite outcome: Doubling of serum creatinine from baseline, initiation of renal replacement therapy or death | Proportion of patients experiencing a component of the composite outcome, defined as a doubling of serum creatinine from the study baseline value, initiation of RRT or death | Within 30 days of randomisation | |
Secondary | Doubling of Serum Creatinine | Proportion of patients with a doubling of serum creatinine from baseline value | Within 30 days of randomisation | |
Secondary | Requirement of Renal Replacement Therapy (RRT) | Proportion of patients requiring RRT | Within 30 days of randomisation | |
Secondary | All-cause mortality | Proportion of patients who have died from any cause | Within 30 days of randomisation | |
Secondary | Vasoactive drug therapy | Proportion of patients who were treated with vasoactive drugs | Within 30 days of randomisation | |
Secondary | Mechanical ventilation | Proportion of patients who required mechanical ventilation | Within 30 days of randomisation | |
Secondary | Ventricular tachycardia or ventricular fibrillation | Proportion of patients who experienced ventricular tachycardia or ventricular fibrillation lasting at least 30 seconds whilst in intensive care | Within 30 days of randomisation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05538351 -
A Study to Support the Development of the Enhanced Fluid Assessment Tool for Patients With Acute Kidney Injury
|
||
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03938038 -
Guidance of Ultrasound in Intensive Care to Direct Euvolemia
|
N/A | |
Recruiting |
NCT05805709 -
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
|
N/A | |
Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|
||
Recruiting |
NCT05897840 -
Continuous Central Venous Oxygen Saturation Measurement as a Tool to Predict Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients
|
N/A | |
Recruiting |
NCT04986137 -
Fractional Excretion of Urea for the Differential Diagnosis of Acute Kidney Injury in Cirrhosis
|
||
Terminated |
NCT04293744 -
Acute Kidney Injury After Cardiac Surgery
|
N/A | |
Completed |
NCT04095143 -
Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury
|
||
Not yet recruiting |
NCT06026592 -
Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
|
||
Not yet recruiting |
NCT06064305 -
Transcriptional and Proteomic Analysis of Acute Kidney Injury
|
||
Terminated |
NCT03438877 -
Intensive Versus Regular Dosage For PD In AKI.
|
N/A | |
Terminated |
NCT03305549 -
Recovery After Dialysis-Requiring Acute Kidney Injury
|
N/A | |
Completed |
NCT05990660 -
Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery
|
N/A | |
Completed |
NCT04062994 -
A Clinical Decision Support Trial to Reduce Intraoperative Hypotension
|
||
Terminated |
NCT02860130 -
Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)
|
Phase 3 | |
Completed |
NCT06000098 -
Consol Time and Acute Kidney Injury in Robotic-assisted Prostatectomy
|
||
Not yet recruiting |
NCT05548725 -
Relation Between Acute Kidney Injury and Mineral Bone Disease
|
||
Completed |
NCT02665377 -
Prevention of Akute Kidney Injury, Hearttransplant, ANP
|
Phase 3 | |
Terminated |
NCT03539861 -
Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients
|
N/A |